Acute Symptomatic Seizures and Risk of Seizure Recurrence in Patients with Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis
Aims To analyze the clinical characteristics of acute symptomatic seizures and predict the risk factors for seizure recurrence in patients with anti-N-methyl- d -aspartate receptor (NMDAR), anti-leucine-rich glioma-inactivated 1 (LGI1), and anti-gamma-aminobutyric acid B receptor (GABA B R) encephal...
Gespeichert in:
| Veröffentlicht in: | Neurological sciences 2024-04, Vol.45 (4), p.1609-1617 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1617 |
|---|---|
| container_issue | 4 |
| container_start_page | 1609 |
| container_title | Neurological sciences |
| container_volume | 45 |
| creator | Cui, Dingge Feng, Jilun Yang, Mu Dong, Yuanyuan Lian, Yajun |
| description | Aims
To analyze the clinical characteristics of acute symptomatic seizures and predict the risk factors for seizure recurrence in patients with anti-N-methyl-
d
-aspartate receptor (NMDAR), anti-leucine-rich glioma-inactivated 1 (LGI1), and anti-gamma-aminobutyric acid B receptor (GABA
B
R) encephalitis.
Methods
In this retrospective study, we included hospitalized patients who had been diagnosed with anti-NMDAR, anti-LGI1, and anti-GABA
B
R encephalitis between November 2014 and April 2021. Binary logistic regression analysis was performed to identify the potential risk factors for seizure recurrence.
Results
In total, 262 patients with anti-NMDAR, anti-LGI1, and anti-GABA
B
R encephalitis were included, 197 (75.2%) of whom presented with acute symptomatic seizures. During follow-up, 42 patients exhibited seizure recurrence. In anti-NMDAR encephalitis, frontal lobe abnormality on brain magnetic resonance imaging, delayed immunotherapy, early seizures, and focal motor onset were associated with seizure recurrence.
Conclusions
Acute symptomatic seizure is a common clinical feature observed in patients with anti-NMDAR, anti-LGI1, and anti-GABA
B
R encephalitis, with 50% of patients presenting with seizures as an initial symptom. The prognosis of patients with acute symptomatic seizures can be improved after receiving immunotherapy. Nevertheless, a minority of patients will experience seizure recurrence; therefore, restarting immunotherapy is recommended. |
| doi_str_mv | 10.1007/s10072-023-07165-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2888036125</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2957621975</sourcerecordid><originalsourceid>FETCH-LOGICAL-c303t-ede91818a12262ec0f695e1cc1d2427bacc520f7fa8c19c2b1a25fec8e4170fe3</originalsourceid><addsrcrecordid>eNp9kctOwzAQRSMEEuXxA6wssWFBwOM87CxTKKVSeaiFteW6E-rSJsV2hGDBt5M2RUgs2Nhj65yrkW4QnAC9AEr5pVufLKQsCimHNAlhJ-hAktEwirnY3c4geLwfHDg3p5RCDFEn-Mp17ZGMP5YrXy2VN5qM0XzWFh1R5ZSMjHslVfHzSUaoa2ux1EhMSR4bAUvvyLvxM5KX3oT3d9f56Lydh_0BnG9iNs9-3s27I9Jr5NVMLYw37ijYK9TC4fH2Pgyeb3pPV7fh8KE_uMqHoY5o5EOcYgYChALGUoaaFmmWIGgNUxYzPlFaJ4wWvFBCQ6bZBBRLCtQCY-C0wOgwOGtzV7Z6q9F5uTRO42KhSqxqJ5kQgkYpsKRBT_-g86q2ZbOdZFnCUwYZX1OspbStnLNYyJU1S2U_JFC5LkO2lcimErmpREIjRa3kGrh8Qfsb_Y_1DRafjVI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2957621975</pqid></control><display><type>article</type><title>Acute Symptomatic Seizures and Risk of Seizure Recurrence in Patients with Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis</title><source>SpringerLink Journals - AutoHoldings</source><creator>Cui, Dingge ; Feng, Jilun ; Yang, Mu ; Dong, Yuanyuan ; Lian, Yajun</creator><creatorcontrib>Cui, Dingge ; Feng, Jilun ; Yang, Mu ; Dong, Yuanyuan ; Lian, Yajun</creatorcontrib><description>Aims
To analyze the clinical characteristics of acute symptomatic seizures and predict the risk factors for seizure recurrence in patients with anti-N-methyl-
d
-aspartate receptor (NMDAR), anti-leucine-rich glioma-inactivated 1 (LGI1), and anti-gamma-aminobutyric acid B receptor (GABA
B
R) encephalitis.
Methods
In this retrospective study, we included hospitalized patients who had been diagnosed with anti-NMDAR, anti-LGI1, and anti-GABA
B
R encephalitis between November 2014 and April 2021. Binary logistic regression analysis was performed to identify the potential risk factors for seizure recurrence.
Results
In total, 262 patients with anti-NMDAR, anti-LGI1, and anti-GABA
B
R encephalitis were included, 197 (75.2%) of whom presented with acute symptomatic seizures. During follow-up, 42 patients exhibited seizure recurrence. In anti-NMDAR encephalitis, frontal lobe abnormality on brain magnetic resonance imaging, delayed immunotherapy, early seizures, and focal motor onset were associated with seizure recurrence.
Conclusions
Acute symptomatic seizure is a common clinical feature observed in patients with anti-NMDAR, anti-LGI1, and anti-GABA
B
R encephalitis, with 50% of patients presenting with seizures as an initial symptom. The prognosis of patients with acute symptomatic seizures can be improved after receiving immunotherapy. Nevertheless, a minority of patients will experience seizure recurrence; therefore, restarting immunotherapy is recommended.</description><identifier>ISSN: 1590-1874</identifier><identifier>EISSN: 1590-3478</identifier><identifier>DOI: 10.1007/s10072-023-07165-1</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Encephalitis ; Frontal lobe ; Glioma ; Glutamate receptors ; Immunotherapy ; LGI1 protein ; Magnetic resonance imaging ; Medicine ; Medicine & Public Health ; N-Methyl-D-aspartic acid receptors ; Neuroimaging ; Neurology ; Neuroradiology ; Neurosurgery ; Original Article ; Psychiatry ; Risk factors ; Seizures ; γ-Aminobutyric acid ; γ-Aminobutyric acid B receptors</subject><ispartof>Neurological sciences, 2024-04, Vol.45 (4), p.1609-1617</ispartof><rights>Fondazione Società Italiana di Neurologia 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c303t-ede91818a12262ec0f695e1cc1d2427bacc520f7fa8c19c2b1a25fec8e4170fe3</cites><orcidid>0000-0002-0422-9078</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10072-023-07165-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10072-023-07165-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Cui, Dingge</creatorcontrib><creatorcontrib>Feng, Jilun</creatorcontrib><creatorcontrib>Yang, Mu</creatorcontrib><creatorcontrib>Dong, Yuanyuan</creatorcontrib><creatorcontrib>Lian, Yajun</creatorcontrib><title>Acute Symptomatic Seizures and Risk of Seizure Recurrence in Patients with Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis</title><title>Neurological sciences</title><addtitle>Neurol Sci</addtitle><description>Aims
To analyze the clinical characteristics of acute symptomatic seizures and predict the risk factors for seizure recurrence in patients with anti-N-methyl-
d
-aspartate receptor (NMDAR), anti-leucine-rich glioma-inactivated 1 (LGI1), and anti-gamma-aminobutyric acid B receptor (GABA
B
R) encephalitis.
Methods
In this retrospective study, we included hospitalized patients who had been diagnosed with anti-NMDAR, anti-LGI1, and anti-GABA
B
R encephalitis between November 2014 and April 2021. Binary logistic regression analysis was performed to identify the potential risk factors for seizure recurrence.
Results
In total, 262 patients with anti-NMDAR, anti-LGI1, and anti-GABA
B
R encephalitis were included, 197 (75.2%) of whom presented with acute symptomatic seizures. During follow-up, 42 patients exhibited seizure recurrence. In anti-NMDAR encephalitis, frontal lobe abnormality on brain magnetic resonance imaging, delayed immunotherapy, early seizures, and focal motor onset were associated with seizure recurrence.
Conclusions
Acute symptomatic seizure is a common clinical feature observed in patients with anti-NMDAR, anti-LGI1, and anti-GABA
B
R encephalitis, with 50% of patients presenting with seizures as an initial symptom. The prognosis of patients with acute symptomatic seizures can be improved after receiving immunotherapy. Nevertheless, a minority of patients will experience seizure recurrence; therefore, restarting immunotherapy is recommended.</description><subject>Encephalitis</subject><subject>Frontal lobe</subject><subject>Glioma</subject><subject>Glutamate receptors</subject><subject>Immunotherapy</subject><subject>LGI1 protein</subject><subject>Magnetic resonance imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>N-Methyl-D-aspartic acid receptors</subject><subject>Neuroimaging</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosurgery</subject><subject>Original Article</subject><subject>Psychiatry</subject><subject>Risk factors</subject><subject>Seizures</subject><subject>γ-Aminobutyric acid</subject><subject>γ-Aminobutyric acid B receptors</subject><issn>1590-1874</issn><issn>1590-3478</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kctOwzAQRSMEEuXxA6wssWFBwOM87CxTKKVSeaiFteW6E-rSJsV2hGDBt5M2RUgs2Nhj65yrkW4QnAC9AEr5pVufLKQsCimHNAlhJ-hAktEwirnY3c4geLwfHDg3p5RCDFEn-Mp17ZGMP5YrXy2VN5qM0XzWFh1R5ZSMjHslVfHzSUaoa2ux1EhMSR4bAUvvyLvxM5KX3oT3d9f56Lydh_0BnG9iNs9-3s27I9Jr5NVMLYw37ijYK9TC4fH2Pgyeb3pPV7fh8KE_uMqHoY5o5EOcYgYChALGUoaaFmmWIGgNUxYzPlFaJ4wWvFBCQ6bZBBRLCtQCY-C0wOgwOGtzV7Z6q9F5uTRO42KhSqxqJ5kQgkYpsKRBT_-g86q2ZbOdZFnCUwYZX1OspbStnLNYyJU1S2U_JFC5LkO2lcimErmpREIjRa3kGrh8Qfsb_Y_1DRafjVI</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Cui, Dingge</creator><creator>Feng, Jilun</creator><creator>Yang, Mu</creator><creator>Dong, Yuanyuan</creator><creator>Lian, Yajun</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0422-9078</orcidid></search><sort><creationdate>20240401</creationdate><title>Acute Symptomatic Seizures and Risk of Seizure Recurrence in Patients with Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis</title><author>Cui, Dingge ; Feng, Jilun ; Yang, Mu ; Dong, Yuanyuan ; Lian, Yajun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c303t-ede91818a12262ec0f695e1cc1d2427bacc520f7fa8c19c2b1a25fec8e4170fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Encephalitis</topic><topic>Frontal lobe</topic><topic>Glioma</topic><topic>Glutamate receptors</topic><topic>Immunotherapy</topic><topic>LGI1 protein</topic><topic>Magnetic resonance imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>N-Methyl-D-aspartic acid receptors</topic><topic>Neuroimaging</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosurgery</topic><topic>Original Article</topic><topic>Psychiatry</topic><topic>Risk factors</topic><topic>Seizures</topic><topic>γ-Aminobutyric acid</topic><topic>γ-Aminobutyric acid B receptors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cui, Dingge</creatorcontrib><creatorcontrib>Feng, Jilun</creatorcontrib><creatorcontrib>Yang, Mu</creatorcontrib><creatorcontrib>Dong, Yuanyuan</creatorcontrib><creatorcontrib>Lian, Yajun</creatorcontrib><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cui, Dingge</au><au>Feng, Jilun</au><au>Yang, Mu</au><au>Dong, Yuanyuan</au><au>Lian, Yajun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute Symptomatic Seizures and Risk of Seizure Recurrence in Patients with Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis</atitle><jtitle>Neurological sciences</jtitle><stitle>Neurol Sci</stitle><date>2024-04-01</date><risdate>2024</risdate><volume>45</volume><issue>4</issue><spage>1609</spage><epage>1617</epage><pages>1609-1617</pages><issn>1590-1874</issn><eissn>1590-3478</eissn><abstract>Aims
To analyze the clinical characteristics of acute symptomatic seizures and predict the risk factors for seizure recurrence in patients with anti-N-methyl-
d
-aspartate receptor (NMDAR), anti-leucine-rich glioma-inactivated 1 (LGI1), and anti-gamma-aminobutyric acid B receptor (GABA
B
R) encephalitis.
Methods
In this retrospective study, we included hospitalized patients who had been diagnosed with anti-NMDAR, anti-LGI1, and anti-GABA
B
R encephalitis between November 2014 and April 2021. Binary logistic regression analysis was performed to identify the potential risk factors for seizure recurrence.
Results
In total, 262 patients with anti-NMDAR, anti-LGI1, and anti-GABA
B
R encephalitis were included, 197 (75.2%) of whom presented with acute symptomatic seizures. During follow-up, 42 patients exhibited seizure recurrence. In anti-NMDAR encephalitis, frontal lobe abnormality on brain magnetic resonance imaging, delayed immunotherapy, early seizures, and focal motor onset were associated with seizure recurrence.
Conclusions
Acute symptomatic seizure is a common clinical feature observed in patients with anti-NMDAR, anti-LGI1, and anti-GABA
B
R encephalitis, with 50% of patients presenting with seizures as an initial symptom. The prognosis of patients with acute symptomatic seizures can be improved after receiving immunotherapy. Nevertheless, a minority of patients will experience seizure recurrence; therefore, restarting immunotherapy is recommended.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><doi>10.1007/s10072-023-07165-1</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-0422-9078</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1590-1874 |
| ispartof | Neurological sciences, 2024-04, Vol.45 (4), p.1609-1617 |
| issn | 1590-1874 1590-3478 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2888036125 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Encephalitis Frontal lobe Glioma Glutamate receptors Immunotherapy LGI1 protein Magnetic resonance imaging Medicine Medicine & Public Health N-Methyl-D-aspartic acid receptors Neuroimaging Neurology Neuroradiology Neurosurgery Original Article Psychiatry Risk factors Seizures γ-Aminobutyric acid γ-Aminobutyric acid B receptors |
| title | Acute Symptomatic Seizures and Risk of Seizure Recurrence in Patients with Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T07%3A11%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20Symptomatic%20Seizures%20and%20Risk%20of%20Seizure%20Recurrence%20in%20Patients%20with%20Anti-NMDAR,%20Anti-LGI1,%20and%20Anti-GABABR%20Encephalitis&rft.jtitle=Neurological%20sciences&rft.au=Cui,%20Dingge&rft.date=2024-04-01&rft.volume=45&rft.issue=4&rft.spage=1609&rft.epage=1617&rft.pages=1609-1617&rft.issn=1590-1874&rft.eissn=1590-3478&rft_id=info:doi/10.1007/s10072-023-07165-1&rft_dat=%3Cproquest_cross%3E2957621975%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2957621975&rft_id=info:pmid/&rfr_iscdi=true |